Eritel

Quick links to important sections

Eritel

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eritel

Property Description
Active Ingredients Amlodipine, Hydrochlorothiazide, Telmisartan
Form Oral tablet
Pharmacological Class Antihypertensive agents (Triple combination)
General Purpose Sustained management of high blood pressure
Origin Synthetic

What Type of Medicine Is Eritel?

Eritel is a prescription-only medication classified as an antihypertensive agent, primarily utilized for the systemic treatment of high blood pressure (hypertension). It is supplied as an oral tablet and functions as a fixed-dose combination (FDC) product, meaning three different active compounds are delivered in a single dosage unit. This pharmaceutical configuration is specifically characterized as a triple-combination product, which is generally indicated when blood pressure control is not adequately achieved using therapies containing only two agents. The convenience of the FDC is often clinically recognized for potentially supporting adherence to complex treatment regimens.


Eritel Composition: A Triple-Combination of Active Ingredients

The drug’s composition consists of three distinct, synthetic active ingredients: Telmisartan, Amlodipine, and Hydrochlorothiazide. Each component belongs to a separate, well-established pharmacological class that targets different aspects of pressure regulation: Telmisartan is an angiotensin II receptor blocker (ARB), Amlodipine is a dihydropyridine calcium channel blocker (CCB), and Hydrochlorothiazide is a thiazide diuretic. The intentional combination of these specific agents utilizes their complementary actions. Combining these three distinct mechanisms provides effective, complementary action for reducing blood pressure.


General Purpose of This Multi-Pathway Therapy

The general purpose of this therapy is to achieve powerful, sustained control over high blood pressure by targeting three separate physiological mechanisms simultaneously. The multi-pathway approach ensures comprehensive lowering of pressure through combined actions of vascular relaxation and systemic fluid management. Eritel is typically selected for adult patients with essential hypertension when their condition is considered resistant or inadequately managed by simpler dual-agent therapies. Its primary role is to stabilize elevated pressure, supporting overall cardiovascular risk reduction.

What side effects are possible with Eritel?

Possible Side Effects and Safety Information

The official safety information for this combination therapy outlines potential adverse reactions categorized by frequency and the body system affected. These classifications are defined in regulatory documents to provide a factual overview of the medicine’s risk profile, separate from its therapeutic uses.


Adverse Reaction Classifications

Adverse effects are documented across various System-Organ Classes, including Vascular disorders, Nervous system disorders, Gastrointestinal disorders, and Renal and urinary disorders.

Frequency Classification Examples of Officially Listed Adverse Reactions
Very Common (ge10%) Peripheral edema
Common (ge1% to <10%) Dizziness, Headache, Edema, Fatigue, Nausea, Diarrhea, Upper respiratory tract infection
Uncommon (ge0.1% to <1%) Syncope, Vertigo, Hypotension, Hyperkalaemia, Renal impairment
Rare (<0.1%) Sepsis, Angioedema, Anaphylactic reaction

Serious adverse reactions explicitly noted in regulatory documents include Sepsis, Angioedema, and Acute renal failure. The drug's safety profile also includes time-related patterns, such as the potential for Hypotension to occur after the initial dose, particularly in patients who are volume- or salt-depleted.


Safety Restrictions and Special Populations

Specific safety restrictions are defined in the labeling. The medication is contraindicated in patients with anuria, known hypersensitivity to sulfonamide-derived drugs, and conditions such as severe hepatic impairment, severe renal impairment (CrCl < 30 mL/min), and during the 2nd and 3rd trimesters of pregnancy. These constraints establish the clear regulatory limits for its use, based on the officially documented risk assessments.

Overdose and Emergency Response

Overdose with the triple combination medication Eritel is officially documented to result from an exaggeration of its intended pharmacological effects, primarily manifesting as profound systemic hypotension. This severe drop in blood pressure can lead to clinical signs such as dizziness and syncope (fainting). The overdose profile also includes potential alterations to the heart rate, presenting as either bradycardia (slow heart rate) or reflex tachycardia (rapid heart rate).

A major concern described in regulatory labeling involves the potential for severe fluid and electrolyte imbalance, notably hypokalemia and hyponatremia, due to the substantial diuretic component. Severe outcomes documented in this context include circulatory shock and the risk of acute renal failure due to systemic hypoperfusion.

Because of these documented life-threatening manifestations, regulatory authorities mandate that immediate medical attention must be sought if an overdose is suspected. Management is defined as symptomatic and supportive, and no specific antidote is known. Procedures documented in overdose management may include placing the patient in the supine position and administering an intravenous infusion of normal saline for severe hypotension. Continuous monitoring of vital signs and serum electrolytes is required, and special considerations exist for patients with impaired hepatic or renal function due to their increased susceptibility to severe effects.

Therapeutic Uses of Eritel

What Eritel Treats: Main Uses and Benefits

This triple-combination therapy is commonly used to help with the systemic, long-term management of essential hypertension, which is relevant in conditions characterized by periods of heightened symptoms (chronic high blood pressure). This medication is generally used in more complex clinical settings, specifically when blood pressure remains inadequately controlled despite the patient using standard dual-agent therapies.

The patient-oriented benefit provides support that helps ease the chronic physical strain on vital organs like the heart and kidneys. The triple combination is considered relevant for easing symptoms that cluster into patterns requiring supportive management, and its use may assist with maintaining functional stability when symptoms of systemic imbalance are more noticeable. The therapeutic context is aligned with areas involving heightened responses.

“The therapy plays a role in managing symptoms linked to organ-specific functional stress, which contributes to improved comfort during periods of heightened symptoms.”


Quick Fact: Relief for Systemic Imbalance

This medication assists with addressing symptoms related to heightened physiological activity and is often applied in scenarios where additional management of systemic discomfort is required.

Regulatory References

  1. NIH Clinical Trials Registry

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Eritel

Eritel's use is strictly defined by official regulatory eligibility rules. The medicine is officially authorized for use only in adult patients with essential high blood pressure that is not adequately controlled by dual-agent therapies.


Contraindicated Populations (Must Not Use)

Use is strictly prohibited (contraindicated) in several populations. These include patients with severe hepatic impairment or biliary obstructive disorders, as well as patients with severe renal impairment, defined as a creatinine clearance less than 30 mL/min, or anuria. It is also contraindicated for patients with refractory hypokalaemia or hypercalcaemia, and those with known hypersensitivity to any of the active substances or related sulfonamide derivatives.


Age and Pregnancy Restrictions

The medicine is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. Use during the first trimester and while breastfeeding is not recommended. Safety and efficacy have not been established in children and adolescents under the age of 18 years, and use in this pediatric population is therefore not recommended.


Conditional Use

Official labeling advises caution or monitoring for patients with mild to moderate hepatic impairment or moderate renal impairment. Special consideration is also given to patients with certain cardiovascular conditions like aortic or mitral valve stenosis.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define a significant interaction profile for this triple combination product (Amlodipine, Hydrochlorothiazide, Telmisartan) based on pharmacokinetic and pharmacodynamic mechanisms.

Classification Interacting Agents / Classes Restriction / Official Outcome
Contraindicated Combinations Aliskiren-containing products Prohibited in patients with diabetes mellitus or renal impairment (GFR < 60 mL/ min/1.73 m^2) due to increased risk of complications [1.2, 2.5].
Exposure Modification Simvastatin Amlodipine component significantly increases Simvastatin systemic exposure; a dose limitation is required [2.1].
Digoxin Telmisartan co-administration increases peak plasma concentration (Cmax) and trough concentration of Digoxin [2.1].
CYP3A4 Inhibitors (e.g., Ketoconazole) Co-administration may increase Amlodipine systemic exposure [2.1].
Pharmacodynamic Risk NSAIDs (including COX-2 Inhibitors) Increased risk of renal function deterioration and potential loss of the antihypertensive effect [2.2, 2.5].
Lithium Concomitant use may result in reversible increases in serum Lithium concentrations and potential toxicity [2.1].
Potassium-elevating Agents Increased risk of hyperkalaemia due to the Telmisartan component [2.5].
Absorption Timing Cholestyramine or Colestipol These agents reduce the absorption of the Hydrochlorothiazide component, necessitating separation of administration by 4 to 6 hours [3.1].

Co-administration with other Angiotensin II Receptor Blockers or ACE Inhibitors is generally avoided (Dual Blockade of the RAAS) due to heightened risks [2.5]. Population-specific constraints note that the use of this medication is contraindicated in severe hepatic impairment [2.7].

Mechanism of Action

Eritel's active pharmaceutical ingredient, telmisartan, functions as a non-peptide angiotensin II receptor blocker (ARB) with high specificity for the Angiotensin II Type 1 (AT1) receptor. It acts as an antagonist, competitively binding to the AT1 receptor sites located on various tissues, including vascular smooth muscle, the adrenal glands, and the kidney. This molecular interaction prevents the endogenous vasoconstrictor, Angiotensin II, from binding and initiating its characteristic cellular cascades.

The intracellular consequence of AT1 receptor blockade is the suppression of signaling pathways that mediate cellular proliferation, cardiac hypertrophy, and vasoconstriction. Specifically, the blockade inhibits Angiotensin II-mediated activation of G-protein coupled pathways and second messenger systems that lead to the release of intracellular calcium.

Downstream, the systemic physiological consequence involves the relaxation and dilation of peripheral blood vessels, which decreases total peripheral vascular resistance. The antagonism also reduces Angiotensin II-stimulated aldosterone secretion, modulating renal reabsorption of sodium and water. The combined effects of reduced vascular tone and decreased circulating volume lead to a sustained modulation of systemic hemodynamics.

Dosage and Administration Information

Official Dosing and Administration Guidelines

Eritel, a fixed-dose combination of Telmisartan, Amlodipine, and Hydrochlorothiazide, is administered according to specific instructions. The medication is not intended for initial therapy and is typically used as a replacement or add-on treatment for adults whose blood pressure remains uncontrolled on dual-agent therapy.


Administration Instructions

Guideline Official Statement
Route & Frequency Must be taken orally as one tablet once daily.
Timing & Food The tablet may be administered with or without food.
Tablet Handling Tablets should be swallowed whole with liquid. Tablets should be kept in the sealed blister until immediately before administration due to their hygroscopic nature.
Dose Adjustment Dose titration is based on blood pressure response and may be increased after a minimum of two weeks.

Population-Specific Use

Prescribing information includes specific rules for certain patient populations:

  • Pediatric Use: The use of this combination is not recommended in children and adolescents (under 18 years) as its safety and efficacy have not been established.
  • Renal Impairment: The fixed-dose combination is not recommended in patients with severe renal impairment (creatinine clearance le 30 mL/min).
  • Hepatic Impairment: The combination is not recommended in severe hepatic impairment. In patients with mild to moderate hepatic impairment, a lower dose of the telmisartan component (e.g., 40 mg once daily) is usually advised.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Eritel (Telmisartan/Amlodipine/Hydrochlorothiazide)

This overview describes the types of clinical studies that have been conducted for Eritel and what the researchers focused on measuring. It is based solely on the official evidence landscape. This information provides context but does not offer clinical advice, specific usage instructions, or predictions about individual outcomes.

Evidence for Use in Essential Hypertension

The research base includes short-term, randomized, controlled clinical trials. These studies examined the triple-combination product in adult patients with a diagnosis of high blood pressure. These trials were designed to compare the combination to the respective dual-drug treatments (Telmisartan/Amlodipine or Telmisartan/Hydrochlorothiazide).

In these research settings, researchers primarily measured the change from baseline in Sitting Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP)—the upper and lower numbers of a pressure reading. Studies monitored this change over typical periods of 8 to 12 weeks. Findings derived from these trials described patterns where a higher percentage of study participants receiving the triple combination attained predefined blood pressure measurement goals. The trials for this specific combination primarily focused on blood pressure readings.

Research on Patients Inadequately Controlled by Dual Therapy

A significant area of research examined the triple combination in patients whose blood pressure remained outside target ranges after using a two-drug combination. These comparative trials explored this combination in populations where previous therapy steps had not resulted in desired pressure measurements.

Studies monitored how blood pressure measurements evolved in this patient population. Studies reported measurements of blood pressure changes after the introduction of the third component, compared to continued dual-agent treatment. Research highlights changes measured during the study period, focusing on patient groups where outcomes related to systemic or functional imbalance were observed.

Long-Term Research and Maintenance of Blood Pressure Control

While the initial comparative trials were short, the research base includes longer follow-up periods. These typically took the form of open-label extension studies, where patients who completed the initial trial continued treatment for up to 52 weeks (one year).

Findings from these open-label extensions described patterns where the initial blood pressure measurements were maintained over the entire observation period. This evidence contributes to understanding how blood pressure measurements evolved during the longer observation periods. However, these longer observational periods are not randomized or double-blinded, and long-term effects are not fully established beyond these maintenance studies.

Evidence in Specific Adult Populations

The clinical studies for Eritel included broad populations of adults. Research examined the product in various patient groups, such as older adults and those with co-existing conditions, including diabetes mellitus.

Studies examined whether the patterns of blood pressure change observed in the overall population were also present in these subgroups. However, data for certain groups remain insufficient, and the results apply only to the populations studied. Limited information is available for highly specialized patient groups, and the overall evidence quality varies across studies concerning complex patient profiles.

Evidence Consistency and Research Limitations

Research describes consistent patterns across the main randomized trials.

However, a key limitation is that the trials focus on blood pressure reduction, which is a surrogate endpoint. Additionally, follow-up durations were limited in the blinded, randomized phase. There is limited information for long-term outcomes, meaning that research provides limited information on hard clinical outcomes (such as the risk of stroke or cardiac events) over several years. Furthermore, there is limited information regarding how this specific fixed-dose pill compares to patients taking the same three medicines as individual pills.

Frequently Asked Questions (FAQ)

Common questions about Eritel (FAQ)


Q: How quickly should I notice the effect of Eritel?

Regulatory documents state that the majority of the blood pressure-lowering effect was apparent within two weeks in clinical studies. The maximal reduction in blood pressure was generally attained after approximately four weeks of treatment.


Q: Can Eritel be used for people with diabetes?

Official regulatory documents define specific limitations regarding use in people with diabetes. The combination product is strictly prohibited from being used concurrently with aliskiren-containing medicines in patients who have diabetes mellitus.


Q: Is it okay to use salt substitutes when taking Eritel?

Official drug labeling advises that potassium-containing salt substitutes should be used with caution. This is because the telmisartan component may increase the risk of elevated potassium levels, a condition known as hyperkalaemia, which is the reason for the caution.


Q: Does the medicine lose its effectiveness over time?

Based on official clinical study data for the telmisartan component, the blood pressure-lowering effect appeared to be maintained for up to one year during long-term observation periods. This evidence describes the observed maintenance of blood pressure control over that period in study participants.


Q: How does Eritel compare to other drugs in the same class?

Official research documentation notes that studies comparing this specific fixed-dose combination pill to other similar single-pill combinations (FDCs) are limited in scope and duration. These comparisons that have been conducted are typically restricted.


Q: Does alcohol use affect the function of Eritel?

Regulatory information states that consuming alcohol may have an additive effect in lowering blood pressure. This additive effect could increase the potential risk of experiencing symptoms such as dizziness, lightheadedness, or fainting.


Q: Does Eritel affect the way I drive or operate machinery?

Because this medicine may cause side effects such as dizziness or drowsiness, official labeling advises caution. Patients are advised against driving or operating hazardous machinery until they are aware of how the medication affects them.


Q: Can Eritel affect my mood or sleep?

Information gathered from clinical experience includes reports of effects on the nervous system. Specifically, side effect information has noted reports of both anxiety and trouble sleeping (insomnia).


Q: Why are people with bilateral renal artery stenosis advised to use caution with Eritel?

Official documents indicate that there is an increased risk of severe low blood pressure and kidney problems for these patients. This heightened risk occurs when using medicines that affect the renin-angiotensin-aldosterone system, like the telmisartan component in Eritel.


Q: Is a blood test required before starting Eritel?

Regulatory information advises that blood tests may be needed at regular intervals or when initiating the medicine. These tests are typically used for monitoring purposes, such as checking kidney function or electrolyte levels.


Q: Are there different strengths of Eritel tablets?

The combination product is supplied in different tablet strengths, according to official labeling. These varying strengths reflect different amounts of the three active components: Telmisartan, Amlodipine, and Hydrochlorothiazide.


Q: Is Eritel a common treatment option for people who cannot tolerate ACE inhibitors?

Telmisartan, one of the components of Eritel, belongs to a class of medicines (Angiotensin II Receptor Blockers or ARBs) that is often used as an alternative to ACE inhibitors. This substitution is typically considered when patients experience certain side effects associated with ACE inhibitors, such as a persistent dry cough.


Q: What happens in the body when Eritel is suddenly stopped?

Official information for the telmisartan component indicates that following abrupt discontinuation, the blood pressure gradually returned to baseline values. This process occurred over a period of several days.


Q: Is it normal to experience a change in heart rate when starting Eritel?

Changes in pulse or heart rate are listed in regulatory documents as a possible symptom that may be experienced. This effect is sometimes observed, particularly at the beginning of treatment or following an adjustment to the dose.


Q: Does taking Eritel make a difference in cholesterol levels?

Some research on the Telmisartan component has examined its ability to affect the levels of certain blood fats, such as triglycerides and cholesterol, in study participants. The evidence base focuses on how these blood fats evolved in the study populations.


Q: How often do I need follow-up appointments when taking Eritel?

Regulatory information emphasizes the importance of having your progress checked by a healthcare provider at regular visits. The regulatory information describes this monitoring process as important for ensuring the medication is working correctly and to check for unwanted effects.


Q: What should be done if I feel unwell shortly after taking Eritel?

Regulatory information advises that signs of a serious allergic reaction, such as swelling of the face or throat, warrant immediate medical attention. Similarly, the occurrence of severe low blood pressure (hypotension) is described as requiring prompt medical attention.

How should Eritel be stored and disposed of?

Official Storage and Disposal Requirements for Eritel

Storage and disposal requirements for Eritel are defined in regulatory documents to maintain product quality and ensure environmental safety.

Storage Conditions:

Requirement Details (According to Official Labeling)
Temperature Store at controlled room temperature, typically below 25 C or 30 C.
Protection Keep the tablets in the original container or sealed blister package to protect them from moisture and light. Avoid excessive heat.
Child Safety The medicine must be kept strictly out of the sight and reach of children.

Disposal Instructions:

Official guidelines state that unused or expired Eritel should not be disposed of in household trash or flushed down the toilet. To ensure proper pharmaceutical waste management and prevent environmental contamination, the product should be returned to a pharmacy or official drug collection point.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Eritel found in:

A-Z Index: